Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Ridker, P M; Rifai, N; Clearfield, M; Downs, J R; Weis, S E; Miles, J S; Gotto, A M

Ridker, P M; Rifai, N; Clearfield, M; Downs, J R; Weis, S E; Miles, J S; Gotto, A M.

Affiliation

Ridker PM; Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA. pridker@partners.org

N Engl J Med ; 344(26): 1959-65, 2001 Jun 28.

Article in En | MEDLINE | ID: mdl-11430324

Subject(s)

Anticholesteremic Agents/therapeutic use; C-Reactive Protein/analysis; Coronary Disease/prevention & control; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Lovastatin/therapeutic use; Acute Disease; Anticholesteremic Agents/pharmacology; Cholesterol/blood; Cholesterol, HDL/blood; Coronary Disease/blood; Double-Blind Method; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology; Lovastatin/pharmacology; Primary Prevention; Proportional Hazards Models; Risk; Risk Factors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: C-Reactive Protein / Lovastatin / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Coronary Disease / Anticholesteremic Agents Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: N Engl J Med Year: 2001 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links